Combination of Androgen Deprivation Therapy with Radical Local Therapy Versus Androgen Deprivation Therapy Alone for Newly Diagnosed Oligometastatic Prostate Cancer: A Phase II Randomized Controlled Trial

医学 雄激素剥夺疗法 前列腺癌 随机对照试验 危险系数 前列腺切除术 泌尿科 放射治疗 内科学 前列腺 无进展生存期 前列腺特异性抗原 置信区间 肿瘤科 外科 癌症 化疗
作者
Bo Dai,Sheng Zhang,Fangning Wan,Hongkai Wang,Junyu Zhang,Qifeng Wang,Yunyi Kong,Xuejun Ma,Miao Mo,Yao Zhu,Xiaojian Qin,Guowen Lin,Dingwei Ye
出处
期刊:European Urology Oncology [Elsevier BV]
卷期号:5 (5): 519-525 被引量:48
标识
DOI:10.1016/j.euo.2022.06.001
摘要

Previous studies suggested that men with metastatic prostate cancer might benefit from local treatment of the primary tumor.To determine whether radical local therapy (RLT) improves survival for men with oligometastatic prostate cancer (OMPCa).This open-label randomized controlled trial included patients with newly diagnosed OMPCa defined as five or fewer bone or extrapelvic lymph node metastases and no visceral metastases.Patients were randomly allocated to androgen deprivation therapy (ADT) or ADT and RLT. Men allocated RLT received either cytoreductive radical prostatectomy (RP) or prostate radiation therapy (RT) with a radical dose schedule.The primary outcome was radiographic progression-free survival (rPFS). Secondary outcomes were overall survival (OS) and prostate-specific antigen (PSA) progression-free survival.Between September 2015 and March 2019, 200 patients were randomized, with 100 men allocated to each group. The median age was 68 yr and the median PSA at diagnosis was 99 ng/ml. In the study group, 96 patients underwent RLT (85 RP and 11 RT). In the control group, 17 patients eventually received RLT (15 RP and two RT). All patients were included for an intention-to-treat analysis. After a median follow-up of -48 mo, the median rPFS was not reached in the study group and was 40 mo in the control group (hazard ratio [HR] 0.43, 95% confidence interval [CI] 0.27-0.70; p = 0.001). The 3-yr OS rate was 88% for the study group and 70% for the control group (HR 0.44, 95% CI 0.24-0.81; p = 0.008).Men with newly diagnosed OMPCa who received ADT plus RLT (mainly prostatectomy) had significantly higher rates of rPFS and OS than those who received ADT alone.This study investigated the effect of radical local therapy (RLT) of the primary tumor on survival in patents with oligometastatic prostate cancer. In our group, RLT improved radiographic progression-free and overall survival.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
泡芙发布了新的文献求助10
刚刚
视野胤发布了新的文献求助10
3秒前
3秒前
善学以致用应助追寻荔枝采纳,获得10
5秒前
5秒前
陌路孤星完成签到,获得积分10
5秒前
6秒前
6秒前
bong发布了新的文献求助10
6秒前
搜集达人应助CL采纳,获得10
7秒前
满意的曼寒应助陌路孤星采纳,获得10
8秒前
9秒前
xiaoyan发布了新的文献求助10
9秒前
NIHGAO完成签到,获得积分20
9秒前
blf发布了新的文献求助10
9秒前
搜集达人应助dild采纳,获得10
9秒前
搞怪世德完成签到,获得积分10
10秒前
10秒前
KinoFreeze完成签到 ,获得积分10
11秒前
11秒前
11秒前
11秒前
庭中踏雪来完成签到 ,获得积分10
12秒前
12秒前
feier完成签到,获得积分10
13秒前
无语的麦片完成签到,获得积分10
14秒前
14秒前
冷傲机器猫完成签到,获得积分10
15秒前
星辰大海应助YQQ采纳,获得10
15秒前
16秒前
Fairy发布了新的文献求助10
16秒前
Hello应助Sir.夏季风采纳,获得10
16秒前
bong完成签到,获得积分10
17秒前
18秒前
19秒前
蔡余文完成签到,获得积分10
19秒前
19秒前
张一诺021222完成签到,获得积分10
19秒前
19秒前
orixero应助sususu采纳,获得10
20秒前
高分求助中
The Mother of All Tableaux Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 2400
Ophthalmic Equipment Market by Devices(surgical: vitreorentinal,IOLs,OVDs,contact lens,RGP lens,backflush,diagnostic&monitoring:OCT,actorefractor,keratometer,tonometer,ophthalmoscpe,OVD), End User,Buying Criteria-Global Forecast to2029 2000
Optimal Transport: A Comprehensive Introduction to Modeling, Analysis, Simulation, Applications 800
Official Methods of Analysis of AOAC INTERNATIONAL 600
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 588
T/CIET 1202-2025 可吸收再生氧化纤维素止血材料 500
Comparison of adverse drug reactions of heparin and its derivates in the European Economic Area based on data from EudraVigilance between 2017 and 2021 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3952868
求助须知:如何正确求助?哪些是违规求助? 3498310
关于积分的说明 11091370
捐赠科研通 3228948
什么是DOI,文献DOI怎么找? 1785159
邀请新用户注册赠送积分活动 869202
科研通“疑难数据库(出版商)”最低求助积分说明 801377